103833-72-3 Usage
Description
Levetiracetam acid, also known as (S)-α-ethyl-2-oxo-pyrrolidine-1-acetamide, is a medication primarily used in the treatment of epilepsy. It is a derivative of the neurotransmitter GABA and has been found to have various effects on the central nervous system. Levetiracetam acid is characterized by its ability to regulate neuronal excitability and inhibit the release of neurotransmitters, which contributes to its anticonvulsant properties.
Uses
Used in Pharmaceutical Industry:
Levetiracetam acid is used as an anticonvulsant medication for the treatment of epilepsy. It is effective in controlling various types of seizures, including partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures. The drug works by modulating the activity of neurotransmitters in the brain, thereby reducing the frequency and severity of seizures.
Used in Research and Development:
Levetiracetam acid is used as a reactant or reagent in the synthesis of various compounds, particularly those related to the treatment of neurological disorders. Its unique chemical structure allows for the development of new drugs with potential applications in the management of epilepsy and other conditions.
Used in Alzheimer's Disease Research:
Levetiracetam acid has been investigated for its potential to inhibit Aβ42/tau aggregation, which is a hallmark of Alzheimer's disease. By preventing the formation of these toxic protein aggregates, Levetiracetam acid may help slow down the progression of the disease and improve cognitive function in affected individuals.
Used in Acetylcholinesterase and Butyrylcholinesterase Inhibition:
Levetiracetam acid has been studied for its inhibitory activities on acetylcholinesterase and butyrylcholinesterase enzymes. These enzymes are involved in the breakdown of the neurotransmitter acetylcholine, which plays a crucial role in cognitive function. By inhibiting these enzymes, Levetiracetam acid may help improve memory and cognitive performance in individuals with Alzheimer's disease and other cognitive disorders.
Used in Acute Toxicity and Docking Studies:
Levetiracetam acid has been utilized in acute toxicity studies to evaluate its safety and potential side effects. Additionally, it has been used in docking studies to investigate the interactions between Levetiracetam-huprine/tacrine hybrids and their target proteins. These studies contribute to the development of more effective anti-Alzheimer's agents and a better understanding of the underlying mechanisms of the disease.
Check Digit Verification of cas no
The CAS Registry Mumber 103833-72-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,3,8,3 and 3 respectively; the second part has 2 digits, 7 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 103833-72:
(8*1)+(7*0)+(6*3)+(5*8)+(4*3)+(3*3)+(2*7)+(1*2)=103
103 % 10 = 3
So 103833-72-3 is a valid CAS Registry Number.
103833-72-3Relevant articles and documents
Scalable Flow Electrochemical Alcohol Oxidation: Maintaining High Stereochemical Fidelity in the Synthesis of Levetiracetam
Zhong, Xing,Hoque, Md Asmaul,Graaf, Matthew D.,Harper, Kaid C.,Wang, Fei,Genders, J. David,Stahl, Shannon S.
supporting information, p. 2601 - 2607 (2021/05/06)
An electrochemical flow process has been developed for an alcohol oxidation step in the synthesis of the generic epilepsy drug levetiracetam. A crucial metric in this process is the retention of high enantiomeric purity as the oxidation of the primary alcohol to the carboxylic acid proceeds via an epimerizable aldehyde intermediate. Here, three different reactor configurations are compared: undivided batch, undivided flow, and divided flow cells. The divided flow cell accesses the highest rate, throughput, and enantiomeric fidelity among the three configurations. This approach is showcased in a 200-g scale process that retains ≥97% enantiomeric purity and highlights a unique advantage of flow electrolysis.
A synthesis of levetiracetam based on (S)-N-phenylpantolactam as a chiral auxiliary
Boschi, Francesca,Camps, Pelayo,Comes-Franchini, Mauro,Munoz-Torrero, Diego,Ricci, Alfredo,Sanchez, Laura
, p. 3739 - 3745 (2007/10/03)
The synthesis of levetiracetam and its enantiomer by deracemization of (±)-2-bromobutyric acid using either (S)- or (R)-N-phenylpantolactam as chiral auxiliaries, followed by SN2 substitution of the bromine atom by a 2-oxopyrrolidin-1-yl group and amidation of the carboxylic acid, is described.
